Clinical Manifestations of Ocular Toxoplasmosis

REFERENCES

• Hogan MJ, Kimura SJ, Lewis A, et al. Early and delayed ocular manifestations of congenital toxoplasmosis. Trans Am Ophthalmol Soc. 1957; 55: 275–296.
   Google Scholar
• Mets MB, Holfels E, Boyer KM, et al. Eye manifestations of congenital toxoplasmosis. Am J Opthalmol. 1996; 122: 309–324.
   PubMed Web of Science ®Google Scholar
• O’Connor GR. Manifestations and management of ocular toxoplasmosis. Bull N Y Acad Med. 1974; 50: 192–210.
   PubMedGoogle Scholar
• McLeod R, Boyer K, Karrison T, et al. Outcomes of treatment of congenital toxoplasmosis,1981–2004,The National Collaborative Chicago-based Congenital Toxoplasmosis Study (NCCCTS). CID. 2006a; 42: 1383–1394.
   PubMed Web of Science ®Google Scholar
• McAuley J, Roizen N, Patel D, et al. Early and longitudinal evaluations of treated infants and children and untreated historical patients with congenital toxoplasmosis: The Chicago Collaborative Treatment Trial. Clin Inf Dis. 1994; 18: 38–72.
   PubMed Web of Science ®Google Scholar
• McLeod R, Mack D, Foss R, et al. Levels of pyrimethamine in sera and cerebrospinal and ventricular fluids from infants treated for congenital toxoplasmosis. Antimicrob Ag Chemother. 1992; 36: 1040–1048.
   PubMed Web of Science ®Google Scholar
• Rothova A. Ocular involvement in toxoplasmosis. Br J Ophthalmol. 1993; 77: 371–377.
   PubMed Web of Science ®Google Scholar
• Roizen N, Kasza K, Karrison T, et al. Impact of visual impairment on measures of cognitive function for children with congenital toxoplasmosis: implications for compensatory intervention strategies. Pediatrics. 2006; 118: e379–e390.
   PubMed Web of Science ®Google Scholar
• Roberts F, Mets MB, Ferguson DJ, et al. Histopathological features of ocular toxoplasmosis in the fetus and infant. Arch Ophthalmol. 2001; 119: 51–58.
   PubMed Web of Science ®Google Scholar
• McLeod R, Kieffer F, Sautter M, et al. Why prevent, diagnose and treat congenital toxoplasmosis? Mem Inst Oswaldo Cruz. 2009 Mar; 104(2): 320–344.
   Google Scholar
• Dodds EM, Holland GN, Stanford MR, et al. Intraocular inflammation associated with ocular toxoplasmosis: relationships at initial examination. Am J Ophthalmol. 2008 Dec;146(6):856–865.
   Google Scholar
• Arun V, Noble AG, and the Toxoplasmosis Study Group. Cataracts in congenital toxoplasmosis. J. Am Assoc Pediatr Ophthalmol Strabismus. 2007 December; 11: 551–554.
   Google Scholar
• Song A, Scott IU, Davis JL, et al. Atypical anterior optic neuropathy caused by toxoplasmosis. Am J Ophthalmol. 2002;133:162–164.
   PubMed Web of Science ®Google Scholar
• Gaynon MW, Boldrey EE, Strahlman ER, et al. Retinal neovascularisation and ocular toxoplasmosis. Am J Ophthalmol. 1984; 98: 585–589.
   Google Scholar
• Fine SL, Owens SL, Haller JA, et al. Choroidal neovascularisation as a late complication of ocular toxoplasmosis. Am J Ophthalmol. 1981; 91: 318–322.
   Google Scholar
• Benevento JD, Jager RD, Noble AG, et al. Toxoplasmosis-associated neovascular lesions treated successfully with ranibizumab and antiparasitic therapy. Arch Ophthalmol. 2008 Aug; 126(8): 1152–1156.
   Google Scholar
• Ben Yahia S, Herbort CP, Jenzeri S, et al. Intravitreal bevacizumab (Avastin) as primary and rescue treatment for choroidal neovascularization secondary to ocular toxoplasmosis. Int Ophthalmol. 2008 Aug; 28(4): 311–316.
   Google Scholar
• Gentile RC, Berinstein DM, Oppenheim R, Walsh JB. Retinal vascular occlusions complicating acute toxoplasmic retinochoroiditis. Can J Ophthalmol. 1997; 32: 354–358.
   PubMed Web of Science ®Google Scholar
• Pakalin S, Arnaud B. Arterial occlusion associated with toxoplasmic chorioretinitis. J Fr Ophtalmol. 1990; 13: 554–556.
   Google Scholar
• Williamson TH, Meyer PA. Branch retinal artery occlusion in toxoplasma retinochoroiditis. Br J Ophthalmol. 1991; 75: 253.
   Google Scholar
• Adan A, Giralt J, Alvarez G, Alforja S, et al. Pars plana vitrectomy for vitreoretinal complications of ocular toxoplasmosis. Eur J Ophthalmol. 2009; 19: 1039–1043.
   PubMed Web of Science ®Google Scholar
• Bosch-Driessen LH, Karimi S, Stilma JS, et al. Retinal detachment in ocular toxoplasmosis. Ophthalmology. 2000; 107: 36–40.
   PubMed Web of Science ®Google Scholar
• Frau E, Gregoire-Cassoux N, Lautier-Frau M, et al. Choriorétinites toxoplamiques compliquées de décollement de rétine. J Fr Ophtalmol. 1997; 10: 749–752.
   Google Scholar
• Boyer, K, Roizen N, Rabiah P, et al. The child with congenital toxoplasmosis. In: Remington JS, ed. Current Clinical Topics in Infectious Diseases. Blackwell Science Inc.; Boston MA 2000:189–207.
   Google Scholar
• Phan L, Kasza K, Jalbrzikowski J, et al. Longitudinal study of new eye lesions in treated congenital toxoplasmosis. Ophthalmology. 2008 Mar; 115(3): 553–559.
   Google Scholar
• Phan L, Kasza K, Jalbrzikowski J, et al. Longitudinal study of new eye lesions in children with toxoplasmosis who were not treated during the first year of life. Am J Ophthalmol. 2008 Sep; 146(3): 375–384.
   Google Scholar
• Guerina NG, Hsu HW, Meissner HC, et al. Neonatal serologic screening and early treatment for congenital Toxoplasma gondii infection. N Engl J Med. 1994; 330: 1858–1863.
   PubMed Web of Science ®Google Scholar
• Vasconcelos-Santos DV, Machado Azevedo DO, Campos WR, et al. Congenital toxoplasmosis in southeastern Brazil: results of early ophthalmologic examination of a large cohort of neonates. Ophthalmology. 2009; 116(11): 2199–205. e1.
   Google Scholar
• Brézin AP, Thulliez P, Couvreur J, et al. Ophthalmic outcomes after prenatal and postnatal treatment of congenital toxoplasmosis. Am J Ophthalmol. 2003; 35: 779–784.
   Google Scholar
• Kieffer F, Wallon M, Garcia P, et al. Risk factors for retinochoroiditis during the first 2 years of life in infants with treated congenital toxoplasmosis. Pediatr Infect Dis J. 2008; 27: 27–32.
   PubMed Web of Science ®Google Scholar
• Kodjikian L, Wallon, Fleury M, et al. Ocular manifestations in congenital toxoplasmosis. Graefes Arch Clin Exp Ophthalmol. 2006; 244: 14–21.
   PubMed Web of Science ®Google Scholar
• Hohlfeld P, Daffos F, Thulliez P, et al. Fetal toxoplasmosis: outcome of pregnancy and infant follow-up after in utero treatment. J Pediatr. 1989; 115: 765–769.
   PubMed Web of Science ®Google Scholar
• Peyron F, Wallon M, Bernardoux C. Long-term follow-up of patients with congenital ocular toxoplasmosis [letter]. N Engl J Med. 1996; 334: 993–994.
   PubMedGoogle Scholar
• Wallon M, Kodjikian L, Binquet C, et al. Long-term ocular prognosis in 327 children with congenital toxoplasmosis. Pediatrics. 2004; 113: 1567–1572.
   PubMed Web of Science ®Google Scholar
• Cortina-Borja M, Tan HK, Wallon M, et al. Prenatal treatment for serious neurological sequelae of congenital toxoplasmosis: an observational prospective cohort study. PLoS Med. 2010; 7(10). pii: e1000351.
   Google Scholar
• Caffos F, Forestier F, Capella-Pavlovsky M, et al. Prenatal management of 746 pregnancies at risk for congenital toxoplasmosis. N Engl J Med. 1988; 318: 271–275.
   Google Scholar
• Foulon W, Villena I, Stray-Pedersen B, et al. Treatment of toxoplasmosis during pregnancy: a multicenter study of impact on fetal transmission and children’s sequelae at age 1 year. Am J Obstet Gynecol. 1999; 180: 410–415.
   PubMed Web of Science ®Google Scholar
• Binquet C, Wallon M, Quantin C, et al. Prognostic factors for the long-term development of ocular lesions in 327 children with congenital toxoplasmosis. Epidemiol Infect. 2003; 131: 1157–1168.
   PubMed Web of Science ®Google Scholar
• Bloch-Michel, Etienne. Ocular toxoplasmosis: clinical aspect. Int Ophthalmol. 1990; 14: 353–357.
   Google Scholar
• Couvreur J, Desmonts G, Aron-Rosa D. Le prognostic oculare de la toxoplasmose congenitale: role du traitement. Ann Pediatr. 1984; 31: 855–858.
   Google Scholar
• Couvreur J, Desmonts G, Tournier G. Etude d’une serie homogene de 210 cas de toxoplasmose congénitale chez des nourrissons ages de 0 à 11 mois et depistes de facon prospective. Sem Hop Paris. 1985; 61: 3015–3019.
   Google Scholar
• Couvreur J. [In utero treatment of congenital toxoplasmosis with a pyrimethamine–sulfadiazine combination.] Presse Med. 1991; 20: 1137.
   Google Scholar
• Couvreur J, Thulliez P, Daffos F, et al. In utero treatment of toxoplasmic fetopathy with the combination pyrimethamine–sulfadiazine. Fetal Diagn Ther. 1993; 8: 45–50.
   Google Scholar
• Desmonts G. Acquired toxoplasmosis in pregnant women: evaluation of the frequency of transmission of Toxoplasma and of congenital toxoplasmosis. Lyon Med. 1982; 248: 115–123.
   Google Scholar
• Thulliez P. Commentary: efficacy of prenatal treatment for toxoplasmosis: a possibility that cannot be ruled out. Int J Epidemiol. 2001; 30:1315–1316.
   Google Scholar
• Röser D, Nielsen HV, Petersen E, et., al. Congenital toxoplasmosis-a report on the Danish neonatal screening programme 1999–2007. J Inherit Metab Dis. 2010; 33(Suppl 2): S241–S247.
   Google Scholar
• Glasner P, Silveira C, Kruszon-Moran D, et al. An unusually high prevalence of ocular toxoplasmosis in southern Brazil. Am J Ophthalmol. 1992; 114: 136–144.
   PubMed Web of Science ®Google Scholar
• Ronday M, Luyendijk L, Baarsma S, et al. Presumed acquired ocular toxoplasmosis. Arch Ophthalmol. 1995; 113: 1524–1529.
   Google Scholar
• Bosch-Driessen E, Rothova A. Recurrent ocular disease in postnatally acquired toxoplasmosis. Am J Ophthalmol. 1999; 128: 421–425.
   PubMed Web of Science ®Google Scholar
• Delair E, Monnet D, Grabar S, Dupouy-Camet J, et al. Respective roles of acquired and congenital infections in presumed ocular toxoplasmosis. Am J Ophthalmol. 2008 Dec; 146(6): 851–855.
   Google Scholar
• Holland G, Muccioli C, Silveira C, et al. Intraocular inflammatory reactions without focal necrotizing retinochoroiditis in patients with acquired systemic toxoplasmosis. Am J Ophthalmol. 1999;128:413–420
   PubMed Web of Science ®Google Scholar
• Noble, AG, Latkany, P, Kusmierczyk, et al. Chorioretinal lesions in mothers of children with congenital toxoplasmosis in the National Collaborative Chicago-based, Congenital Toxoplasmosis Study. Sci Med. 2010 20(1):20–26.
   Google Scholar
• Koppe JG, Kloosterman GJ. Congenital toxoplasmosis: long-term follow-up. Padiatr Padol. 1982; 17: 171–179.
   PubMed Web of Science ®Google Scholar
• Koppe JG, Loewer-Sieger DH, DeRoever-Bonnet H. Results of 20-year follow-up of congenital toxoplasmosis. Lancet. 1986; 1: 254–256.
   PubMed Web of Science ®Google Scholar
• Bosch-Driessen LE, Berendschot TT, Ongkosuwito JV, et al. Ocular toxoplasmosis: clinical features and prognosis of 154 patients. Ophthalmology. 2002 May; 109(5): 869–878.
   Google Scholar
• Holland GN, Crespi CM, ten Dam-van Loon N, et al. Analysis of recurrence patterns associated with toxoplasmic retinochoroiditis. Am J Ophthalmol. 2008 Jun; 145(6): 1007–1013.
   Google Scholar
• Silveira C, Belfort R Jr, Muccioli C, et al. The effect of long-term intermittent trimethoprim/sulfamethoxazole treatment on recurrences of toxoplasmic retinochoroiditis. Am J Ophthalmol. 2002; 134: 41–46.
   PubMed Web of Science ®Google Scholar
• Jamieson SE, de Roubaix LA, Cortina-Borja M, et al. Genetic and epigenetic factors at COL2A1 and ABCA4 influence clinical outcome in congenital toxoplasmosis.PLoS ONE. 2008; 3: e2285.
   Web of Science ®Google Scholar